The insulin-like growth factors (IGFs) have been implicated in the autocrine and/or paracrine growth of a number of tumor types, including lung tumors. Importantly, insulin-like growth factor-binding proteins (IGFBPs), which both enhance and inhibit the physiological and biological actions of the IGFs, have been shown to be secreted in vitro by a wide range of tumors. In particular, IGFBP-2 is frequently produced by human tumor cells, suggesting that this protein may be an
INTRODUCTION
Several reports have shown that SCLC 2 cell lines secrete and respond to exogenous IGFs, indicating an autocrine role for these peptides in SCLC cell proliferation (1--6) . Although molecular characterization of SCLC-secreted IGFs has not been formally addressed, recent reverse transcriptase-polymerase chain reaction studies indicate that approximately 50% of SCLC and 30% of NSCLC cell lines express the IGF-I gene and that almost all SCLC and NSCLC lines show IGF-II gene expression (7) . In addition to IGF secretion, lung tumor cell lines also secrete an array of IGFBPs (3, (7) (8) (9) . Six distinct classes of these proteins have been identified to date: IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6 (10, 11) . These proteins bind the IGFs, often with different relative affinities, and in so doing are thought to modulate the physiological and cellular Received 3/3/93; accepted 7/28/93. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom requests for reprints should be addressed, at MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge, CB2 2QH, England.
2 The abbreviations used are: SCLC, small cell lung cancer; IGFs, insulin-like growth factors; NSCLC, non-small cell lung cancer; IGFBPs, insulin-like growth factor-binding proteins; rh, recombinant human; BSA, bovine serum albumin; SDS, sodium dodecyl sulfate; Cys, cysteine.
actions of these peptides (12) . Our recent studies have shown that coexpression of multiple binding protein genes occurs in several lung tumor cell lines (7) . However, whereas IGFBP-1 and IGFBP-3 were variably and often weakly expressed in lung tumor cell lines, all SCLC and NSCLC cell lines showed a high level of IGFBP-2 gene expression. Interestingly, a follow-up study of IGFBP production in a wide variety of tumor types showed IGFBP-2 expression in all cell lines derived from solid tumors (13) . These findings raise the possibility that IGFBPs, and particularly IGFBP-2, may influence tumor cell responsiveness to the autocrine and/or paracrine actions of the IGFs. In the present study, we addressed this question in lung tumors by investigating the effect of IGFBP-2 on IGF-receptor interaction and the biological actions of IGF-I and IGF-II.
MATERIALS AND METHODS
Cells. The SCLC cell line NCI-H69 was donated by Drs. D. Carney and A. Gazdar (National Cancer Institute, Navy Medical Oncology Branch, Bethesda, MD). The derivation and characterization of the SCLC cell lines COR-L88, COR-L32, COR-IA2, COR-L47, and COR-L51 and the large cell NSCLC cell line COR-L23 have been described previously (14) . These, together with the squamous cell lung carcinoma cell line BEN and the lung adenocarcinoma cell line MOR, were obtained from Dr. P. R. Twentyman, and the squamous cell lung cancer cell line LUDLU-1 was kindly supplied by Dr. P. H. Rabbitts (both from the Clinical Oncology and Radiotherapeutics Unit, Medical Research Council Centre, Cambridge, United Kingdom). All cell lines were routinely grown in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% fetal calf serum, 10 /zg penicillin/ml, and 10/xg streptomycin/ml (all Gibco BRL, Paisley, Scotland).
Peptides and Radiochemicals. Recombinant IGF-I and IGF-II were obtained from Calbiochem (Nottingham, United Kingdom) or from Amersham International (Aylesbury, United Kingdom). lzsI-IGF-I (specific activity, 2000 Ci/mmol), 12sI-IGF-II (specific activity, 2000 Ci/mmol), [6-3H] thymidine (specific activity, 27 Ci/mmol), and [methyl-laC]thymidine (specific activity, 57 mCi/mmol) were purchased from Amersham International. The production and characterization of Cys 281 rh IGFBP-2 have been described elsewhere (15, 16) . The rabbit anti-type-I receptor antiserum (aiR3) (17) was obtained from Cambridge Bioscience (Cambridge, United Kingdom), and rabbit anti-IGFBP-2 antiserum was from Upstate Biotechnology Inc. (Lake Placid, NY).
Characterization of IGF-binding Sites. Cells in exponential growth were harvested either using a cell scraper for adherent cultures of MOR or by centrifugation for the COR-L88 suspension culture. After three washes in phosphate-buffered saline containing 0.8 mg pepstatin/ml, 2 mg aprotinin/ml, and 2 mg leupeptin/ml, cells were resuspended on ice in lysis buffer consisting of 1 mM Tris base containing 0.8 mg pepstatin/ml, 2 mg aprotinin/ml, and 2 mg leupeptin/ml. Ceils were disrupted by sequential passage through 21-and 26-gauge syringe needles. The suspension was then centrifuged at 450 • g at 4~ for 10 min. The resulting supernatant was further centrifuged at 50,000 • g for 1 h. The pellet was resuspended in lysis buffer, and protein determinations were carried out.
Cell membranes (50 /~g) were incubated at 25~ with 125I-IGF-I or 125I-IGF-II (1 • 106cpm) in 5 mM Tris buffer with 0.5% BSA in the presence or absence of unlabeled 100 nM IGF-I, 100 nM IGF-II, 10 p~g/ml insulin, or 10 /xg/ml MR3. In experiments in which anti-receptor antibody was used, membranes and antibody were preincubated for 1 h at room temperature before the addition of the radiolabeled peptide. The samples were incubated at room temperature in a final volume of 1 ml for 2.5 h. The samples were washed with 1 ml of buffer and centrifuged at 4500 • g for 10 min at 4~ The pellet was resuspended in 1 ml 5 mM Tris buffer without BSA, and the radiolabeled 4680
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on January 5, 2018. © 1993 American Association for Cancer cancerres.aacrjournals.org Downloaded from peptide was cross-linked with 10 pJ 10 mM disuccinimidyt suberate in 100% dimethyl sulfoxide at 4~ and pH 7.4. The cross-linking reaction was quenched after 15 min by the addition of 200 /~1 50 mM Tris-HCl and 5 mM EDTA, followed by a second centrifugation. The samples were then solubilized in SDS sample buffer, boiled for 5 min, and subsequently electrophoresed together with molecular weight markers (Gibco BRL, Paisley, United Kingdom) under nonreducing conditions on a 3-15% acrylamide gel at constant current. The gels were dried and autoradiographed.
Immunoprecipitation and Immunoblotting of Membrane-associated
IGFBP-2. For immunoprecipitation studies, 200 /.Lg of membrane protein from COR-L88 were cross-linked to radiolabeled IGF-I/II as described above. Pelleted membranes were resuspended in a solution containing 50 mu Tris base (pH 7.4), 150 mM NaCI, 0.01% NaN3 (buffer A), protease inhibitors at the concentration previously given, and 2% Triton X-100 and incubated for 1 h at 4~ Following addition of 0.5 ml buffer B, solubilized membranes were centrifuged at 30,000 rpm for 30 min at 4~ and t:1000 dilution of rabbit anti-IGFBP-2 was added to the supernatant. After the membrane-protein/ antibody solution was incubated overnight at 4~ 25 p,l of pansorbin (Calbiochem, Nottingham, United Kingdom) were added and incubated for 1 h at 4~ The pansorbin was pelleted by centrifugation at 6500 rpm and the pellet washed twice with buffer A. The pellet was then incubated in 2 • SDS sample buffer for 30 min at 4~ and was subsequently boiled for 30 s. Immunoprecipitated proteins were electr6phoresed on a 12.5% SDS-polyacrylamide gel under nonreducing conditions followed by autoradiography.
For immunoblotting studies, 100/~g of membrane proteins from SCLC cell lines COR-L88, NCI-H69, COR-L42, COR-LA7, and COR-LS1 and from NSCLC cell lines MOR, COR-L23, LUDLU-1, and BEN were electrophoresed on a 12.5% SDS-polyacrylamide gel under nonreducing conditions. Proteins were transferred to nitrocellulose paper as described elsewhere (18) . After transfer, additional protein-binding sites on the nitrocellulose paper were blocked by incubation overnight in 5 mM EDTA, 0.25% gelatin, 0.01 M NAN3, 0.15 M NaCI, 0.05 M Tris base, and 0.05% Nonidet P-40. The paper was then incubated overnight at 4~ with rabbit anti-IGFBP-2 antiserum (1:1000 in the previously described buffer). After the paper was washed, affinity-purified 125I-protein A was used to visualize anti-IGFBP2 antibody binding.
Ligand-binding Assays. For IGF receptor assays, membrane samples (100 p,g protein) were incubated overnight at 4~ with ~25I-labeled IGF-I/IGF-II (50 pM) and appropriate dilutions of cold peptide in a final volume of 0.25 ml of 20 mu Tris-HCl, 10 mM MgC12 (pH 7.5) containing 0.2% bovine serum albumin (buffer B). Nonspecific binding was determined by adding an excess of 100 nu IGF-I/IGF-II. Membrane-bound and free peptide were separated by centrifugation, followed by a single wash in ice-cold buffer B. The radioactivity associated with pelleted membranes was determined in a gamma counter. Determination of binding parameters was performed using the nonlinear least squares fitting program Enzfitter (Biosoft, Cambridge, United Kingdom).
To investigate the influence of soluble IGFBP-2 on IGF-cell interaction, L88 and MOR cells seeded into 24-well plates (2 x 105 cells/well) were washed twice in phosphate-buffered saline and incubated at 4~ for 90 rain in 0.5 ml binding buffer containing 0.1 M 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid-0.12 M NaC1-5 mM KCI-I.2 mM MgSO4-8 mM glucose-25 mg BSA/ml, pH 7.6), 105 cpm (50 pu) 12sI-IGF-I or 125I-IGF-II in the presence or absence of 100 nM cold IGF-I, 100 nM cold IGF-II, or 0.1 riM-100 nM IGFBP-2. Cells were subsequently washed briefly in ice-cold binding buffer, and cellassociated radioactivity was determined on a gamma counter.
DNA Synthesis Assay. Prior to IGF/IGFBP-2 treatment, cells were prelabeled with 0.25 p, Ci/ml [14C]thymidine in RPMI 1640 medium containing 10% fetal calf serum to provide an internal standard to control for potential variation in cell number per well in the DNA synthesis assay. Cells were incubated in serum-free RPMI 1640 medium for 96 h to effect growth arrest. To determine whether cells had become growth arrested, cultures were then treated with 60 ng colcemid/ml for 24 h and subjected to flow cytometric cell cycle analysis to detect the presence or absence of G2 arrest. Cultures showing no evidence of G2 accumulation were considered growth arrested; those showing G2 accumulation were considered actively cycling.
Cells were removed from the tissue culture flasks by incubation in 0.02% EDTA for 10 min (NSCLC), or by centrifugation (SCLC), followed by washing in serum-flee RPMI 1640 medium. Cells (2 • 104/well) were then seeded into 96-weU plates in RPMI 1640 medium supplemented with 10 p~g transferrin/ml and 0.8 ng/ml sodium selenite (1) and treated with either 0.1-100 nM IGF-I or 0.1-100 nM IGF-II in the presence or absence of equimolar concentrations of IGFBP-2. After the cells were incubated at 37~ for 20 h, 0.1 /xCi [3H]thymidine was added per well, and the cells were incubated for a further 20 h. Cells were then lysed in 0.1% SDS followed by treatment with 10% trichloroacetic acid. Trichloroacetic acid-precipitable material was then harvested onto Whatman GSF filters (Semat Technical Ltd., St. Albans, United Kingdom).
Statistical Analyses. The concentration dependence of IGF-I, IGF-II, and IGFBP-2 effects on DNA synthesis, either alone or combined as described above, was investigated using analysis of variance. No significant concentration dependence was observed for any of the treatments. On the basis of this finding all data pertaining to a particular treatment group were pooled. A 2-tailed, unpaired T test on pooled data (n = 15) was used to compare stimulation of DNA synthesis by IGF-I and IGF-II. A single group T test on pooled data was used to compare changes in DNA synthesis for each treatment group relative to control, untreated cells with a group mean value of 1. Analyses were carried out using the Statworks 512 program on a Macintosh SE/30 computer.
R E S U L T S
Characterization o f I G F Binding to N S C L C . Under nonreducing conditions in the absence of competing peptide 125I-IGF-I was cross-linked to proteins which migrated with estimated Mr >300,000
( Characterization of IGF Binding to SCLC Cells. Under nonreducing conditions in the absence of competing peptide 125I-IGF-I was cross-linked predominantly to a protein which migrated as a complex with apparent Mr 37,000 (Fig. 1B, lane 1 ) . Cross Under nonreducing conditions in the absence of competing peptide, 125I-IGF-II was cross-linked predominantly to a protein which migrated as a complex with apparent Mr 37,000 (Fig. 1B, lane 6) . 37,000 125I-IGF-II-protein complex as shown in Fig. 2 . Immunoprecipitated IGFBP-2 was made up of a protein doublet. SDS-polyacrylamide gel electrophoresis of membrane proteins followed by immunoblotting with anti-IGFBP-2 antiserum (Fig. 3) demonstrated the presence of membrane-associated immunoreactive protein in COR-L88 and MOR which again appeared as a doublet. It can be seen that more membrane-associated immunoreactive IGFBP-2 is present in SCLC cell line COR-L88 than in NSCLC cell line MOR. COR-L88 cells grown under serum-free conditions failed consistently to show an increase in DNA synthesis compared to untreated controls following treatment with 0.1-100 nM IGF-I and IGF-II in the presence or absence of IGFBP-2 (data not shown). Fig. 6 shows that treatment of growth-arrested MOR cells with IGF-I resulted in stimulation of DNA synthesis compared to untreated controls. The observed increase in DNA synthesis was maximal at 0.01 nu and did not increase further with higher concentrations of IGF-I. Addition of equimolar concentrations of IGFBP-2 had no significant effect on IGF-I-stimulated DNA synthesis. and in vivo (3, 7-9) . Indeed, the synthesis and secretion of IGFBPs appear to be a property common to many different tumor cells, with IGFBP-2 being produced most frequently (13) . An important finding of the present study was the detection of abundant membrane-associated IGFBP-2 in some, but not all, lung tumor cell lines. Interestingly, membrane-associated IGFBP-2 was readily detected by immunoblotting in SCLC cell line COR-L88 and in all other SCLC cell lines studied but was present at much lower levels in NSCLC cell line MOR and three other NSCLC cell lines examined. Importantly, immunoblotting of IGFBP-2 in lung tumor cell-conditioned media showed no consistent difference in the amount of IGFBP-2 secreted by SCLC and NSCLC cells, indicating that the differences in membrane-associated IGFBP-2 in SCLC and NSCLC cells are not a consequence of differences in IGFBP-2 secretion. Studies are in progress to investigate the nature of IGFBP-2-membrane interaction.
The importance of membrane-associated binding protein is indicated by membrane cross-linking studies which show that in the presence of low levels of membrane-associated IGFBP-2, as in NSCLC cell line MOR, the IGFs bind to the type-I and type-II receptors, whereas in the presence of abundant membrane-associated binding protein, as in SCLC cell line COR-L88, the IGFs bind predominantly to membrane IGFBP-2, with relatively little binding to IGF receptors. The importance of membrane-associated IGFBP-2 in determining IGF-receptor interaction is further exemplified by the observation that, in SCLC cell line COR-L88, binding of 125I-IGF-II to the type-II receptor can only be detected in the presence of excess IGF-I, which presumably displaces 125I-IGF-II from surface IGFBP, allowing binding to the type-II receptor which has a lower affinity for IGF-I than has IGFBP-2. These findings suggest that cell surfaceassociated IGFBP-2 acts as a reservoir of IGF-binding sites which effectively compete with IGF receptors for ligand binding. This contention is supported by the findings of others (6) which indicate that Column, mean of 3 individual determinations. P values were obtained as described in "Materials and Methods" and have been calculated for the difference between the mean pooled data for each treatment (n = 15) and the group control of 1.
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on January 5, 2018. © 1993 American Association for Cancer cancerres.aacrjournals.org Downloaded from cell line. The latter finding does not appear to be consistent with reports demonstrating that secreted IGFBPs have a higher affinity for ligand when in solution than when adherent to cell surfaces (19, 20) , since concentrations of IGFBP-2 in excess of 10 nu were required to make a significant impact on ~25I-IGF-I and -II binding to COR-L88. The inhibitory action of soluble IGFBP-2 on ligand-receptor interaction and IGF-induced DNA synthesis in NSCLC cell line MOR is consistent with the contention that secreted/exogenous IGFBPs can act as blocking agents preventing IGF association with cell surface receptors. Similar observations have been made for IGFBP-1 and IGFBP-3 which block the cell surface association of radiolabeled IGF-I and which can inhibit either cell proliferation and/or cell function in a variety of different cell types (21) (22) (23) (24) .
The marked difference in the amount of surface-associated IGFBP-2 in SCLC and NSCLC cells and the influence this appears to have on IGF-receptor interaction suggest that the responsiveness of the two different histological types of lung cancer to IGF stimulation may be very different. The finding that the SCLC cell line COR-L88 failed to respond to IGF-I and IGF-II stimulation, whereas the NSCLC cell line MOR, having relatively little surface-associated IGFBP-2, did show increased DNA synthesis particularly following stimulation with IGF-II, may be supportive of a role for surface IGFBP-2 in the regulation of IGF responsiveness. However, the nonresponsiveness of COR-L88 to IGF stimulation may be related to the finding that these cells could not be growth arrested and were actively cycling at the time of IGF treatment. Further studies are needed to clarify the relationship between membrane IGFBPs and IGF responsiveness. Although others have reported convincing increases in DNA synthesis in only 2 of 7 SCLC cell lines (1) using a similar DNA synthesis assay as a measure of IGF responsiveness, in vitro cell proliferation (2) and clonogenic assays (6), both of which involve prolonged exposure to IGF stimulation, do indicate that IGF-I and -II promote SCLC cell proliferation in the majority of cell lines studied under these conditions. Such findings may indicate that exogenous IGFs are released eventually from surface IGFBP-2 and then interact with IGF receptors to stimulate cell proliferation. Importantly, bound IGFs have been shown to be released from membrane-associated IGFBP-3 via a timedependent process which decreases the affinity of IGFBP-3 for bound IGFs (20) . Thus, while surface (and secreted) IGFBP-2 and other IGFBPs may be perceived as reservoirs for the IGFs which initially compete with IGF receptors for ligand binding, they may function to maintain high concentrations of IGFs in the tumor cell environment by releasing the IGFs in a time-dependent manner.
An unexpected finding in the present study( as demonstrated by cross-linking studies is that 125I-IGF-II preferentially binds to the IGF-I receptor and not to the type-II receptor in the NSCLC cells. 125I-IGF-II binding to the type-II receptor was only detected in the presence of saturating concentrations of IGF-I which displaced IGF-II from the type-I receptor, allowing it then to bind to the type-II receptor. We believe that the data obtained from ligand-binding and competition studies can best be interpreted by postulating that both IGF-I and IGF-II bind to the type-I receptor with almost equal affinity, an observation also reported for the IGF-I receptor from human brain (25) . The apparent difference in the calculated maximum binding capacities for 125I-IGF-I and 125I-IGF-II binding is probably artifactual and a manifestation of the higher nonspecific binding obtained for 125I-IGF-II. The finding that ot-IR3, a highly specific monoclonal antibody to the type-I receptor, inhibited the binding of 125I-IGF-I but not of 125I-IGF-II to the type-I receptor on MOR cells may indicate existence of two distinct IGF-binding sites on the type-I receptor of these cells, as previously described for IGF-I receptors on human placenta (26) . Interestingly, IGF-II proved to be a more potent mitogen than IGF-I for MOR, an observation which cannot be explained 4684
on January 5, 2018. © 1993 American Association for Cancer cancerres.aacrjournals.org Downloaded from by simple cross-reaction with the type-I receptor, and it may be that interaction with a discrete, high-affinity site on the type-I receptor for IGF-II binding mediates the biological effects of IGF-II in these lung tumor cells. We reported previously the ubiquitous expression of the IGF-II gene in lung tumor cell lines. In contrast, expression of the IGF-I gene was detected in only approximately 30% of lines studied (7) . This led to speculation that IGF-II may be more widely involved in the autocrine growth of lung tumors. The findings of the present study lend support to this contention and, further, identify the likely involvement of high-affinity IGF-II binding sites on IGF-I receptors in the growth-promoting action of IGF-II.
The present study indicates that, in lung tumor cells, regulation of the cellular action of the IGFs depends on a complex interplay among surface-associated IGFBP-2, extracellular IGFBP-2, and IGF receptors and possibly IGF receptor subtypes, Since we and others have shown the coexpression of multiple different IGFBPs by lung tumor cell lines, the scenario is likely complicated further by the actions of other membrane and secreted IGFBPs. The various forms of IGFBP may play distinct roles in controlling the availability of IGFs to tumor cells and their receptors, in regulating the half-life of circulating IGF, or in modulating the biological activity of the IGFs. The rate of secretion of a particular form of IGFBP and its degree of cell surface association may all contribute to the control of IGF action: in the case of IGFBP-3, it has been shown that association with the cell membrane is an important factor in the potentiation of IGF action by this IGFBP (27) . Indeed, we recently detected IGFBP-3 in the membranes of MOR and other NSCLC cell lines and are currently investigating the action of this protein in these cells. 3 The finding that the association of IGFBP-3 with the cell membrane potentiates IGF action raises the possibility that other membrane-associated IGFBPs have similar actions. Hence, in COR-L88 membrane-associated IGFBP-2 may potentiate the mitogenic action of endogenously produced IGFs to such an extent that exogenous IGF has no additional effect in these cells. In this regard, purified IGFBP-2 has been shown to potentiate the mitogenic activity of IGF-I on porcine smooth muscle cells (28) , perhaps by enhancing receptor activation or by a receptor-independent effect. Such findings together with those of the present study indicate the potential growth-promoting and -inhibiting actions of the IGFBPs and highlight the need for further information regarding the roles of individual IGFBPs in controlling growth of a particular tumor type before these agents are considered as pharmacological neutralizers of IGF action for tumor growth control.
